Annual LCR urine screening would cut cost of chlamydia treatment, study shows.
This article was originally published in The Gray Sheet
Executive Summary
ANNUAL URINE SCREENING WITH LCR WOULD HALVE CHLAMYDIA TREATMENT COSTS IN U.S., according to a study presented by Max Chernesky, PhD, St. Josephs Hospital, Hamilton, Ontario, at the recent American Association of Clinical Chemistry conference in Chicago. The study, which used a computer-based economic model to analyze data from published literature, showed that instituting an annual urine screening program using a ligase chain reaction probe assay could reduce "to less than $400 mil. a year from over $1 bil." the cost of treating certain diseases caused by chlamydia.